Boston Scientific: A Q3 Earnings Miss Likely Amid Product Recall, Cybersecurity Incident

Impact · against what's priced in

The article provides no new catalyst for BSX, as the market has already priced in the cyberattack, decelerating core growth, and recent guidance cuts. The outlook remains neutral-to-bearish, but the current valuation reflects these operational headwinds.

BSX−0.05

Already priced in

The price assumes

The cyberattack disruption and its drag on near-term shipments and operations

The warning of a likely Q3 earnings miss due to the cybersecurity incident and product recalls aligns with the market's current refusal to pay for a recovery from these specific events.